PATENTSCOPE: EN_ALL:nmr AND PA:lilly

CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS (Fri, 15 Mar 2019)
A compound of the formula (I) wherein Q is selected from the group consisting of -C(CH 3) 2and (II); R is selected from the group consisting of (III) and (IV); or a pharmaceutically acceptable salt thereof; compositions, methods to treat liver disease and NASH.
>> Read More

IMIDAZOLIDINE COMPOUNDS (Fri, 15 Mar 2019)
The present invention provides a compound of Formula (I) wherein X is selected from the group consisting of -(CH2)2- and -CH2-CH (CH3)-; Q is selected from the group consisting of -C(CH3)2 and (II) or a pharmaceutically acceptable salt thereof; compositions, methods to treat liver disease and NASH.
>> Read More

CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS (Fri, 15 Mar 2019)
Provided are compounds of Formula (I), pharmaceutically acceptable salt thereof, compositions and methods to treat liver disease and NASH.
>> Read More

IMIDAZOLIDINE COMPOUNDS (Fri, 15 Mar 2019)
The present invention provides a compound of Formula (I) wherein X is selected from the group consisting of (CH2)2- and CH2-CH(CH3)-; Q is selected from the group consisting of C(CH3)2 and Formula (a); or a pharmaceutically acceptable salt thereof; compositions, methods to treat liver disease and NASH.
>> Read More

LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS (Fri, 08 Mar 2019)
A compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.
>> Read More

LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS (Fri, 08 Mar 2019)
The present invention provides a compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.
>> Read More

[1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES (Fri, 15 Feb 2019)
The present invention provides a compound of Formula I: wherein X is CH2CH2, CH2CH2CH2, OCH2, or CH2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH2CH2, then R is other than cyclopropyl; for use as a human PDE1 inhibitor.
>> Read More

[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-6(5H)-ONE DERIVATIVES (Fri, 08 Feb 2019)
The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluorom ethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDEl inhibitor.
>> Read More

5-METHYL-1,3,4-OXADIAZOL-2-YL COMPOUNDS (Fri, 30 Nov 2018)
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimers disease.
>> Read More

CGRP RECEPTOR ANTAGONISTS (Fri, 23 Nov 2018)
The present invention provides compounds of Formula II or a pharmaceutically acceptable salts thereof, useful as a CGRP receptor antagonist.
>> Read More

3-METHYL-PYRROLIDINE-2,5-DIONE DERIVATIVES USEFUL AS CGRP RECEPTOR ANTAGONISTS (Fri, 23 Nov 2018)
The present invention provides a compound of Formula II or a pharmaceutically acceptable salt or hydrate thereof, useful as a CGRP receptor antagonist.
>> Read More

PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS (Fri, 26 Oct 2018)
The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical compositions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer.
>> Read More

ISOQUINOLIN AND NAPHTHYDRIN COMPOUNDS (Sat, 08 Sep 2018)
The present invention provides a compound of Formula (I), where in X is selected from the group consisting of CH and N; Q is selected from the group consisting of CH3 and H; R is selected from the group consisting of (II) and (III), or a pharmaceutically acceptable salt thereof, compositions, methods to treat liver disease and NASH.
>> Read More

ISOQUINOLIN AND NAPHTHYDRIN COMPOUNDS (Sat, 08 Sep 2018)
The present invention provides a compound of Formula I I wherein X is selected from the group consisting of CH and N; Q is selected from the group consisting of CH3 and H; R is selected from the group consisting of and; or a pharmaceutically acceptable salt thereof, compositions, methods to treat liver disease and NASH.
>> Read More

COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T (Sat, 08 Sep 2018)
The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A).
>> Read More

DIAZASPIRODECANYL-PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS (Fri, 24 Aug 2018)
The present invention provides a compound of the Formula (1) below pharmaceutically acceptable salts of the compound of Formula (1), methods of treating patients for liver disease, and processes for preparing the compounds.
>> Read More

AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS (Fri, 24 Aug 2018)
The present invention provides compounds of the formula below, pharmaceutically acceptable salts of the compounds, methods of treating patients for liver disease, and processes for preparing the compounds.
>> Read More

AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS (Fri, 24 Aug 2018)
The present invention provides compounds of the formula (1) pharmaceutically acceptable salts of the compounds, methods of treating patients for liver disease, and processes for preparing the compounds.
>> Read More

N-[4-FLUORO-5-[[(2S,4S)-2-METHYL-4-[(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHOXY]-1-PIPERIDYL]METHYL]THIAZOL-2-YL]ACETAMIDE AS OGA INHIBITOR (Fri, 03 Aug 2018)
The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula (I) for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
>> Read More

7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS (Fri, 22 Jun 2018)
A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
>> Read More